FDA Approves ‘Illuminating’ Drug for Spotting Cancer
A bio-tech company based out of the Purdue Research Park has developed a potential game changer in identifying ovarian cancer. The FDA has approved the use of On Target Laboratories’ fluorescent imaging agent CYTALUX to target cancer during surgery. We get details from On Target Laboratories Chief Science Officer & Founder Dr. Philip Low.
Video Player is loading.
This is a modal window.
The media could not be loaded, either because the server or network failed or because the format is not supported.